Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Esslingen Am Neckar – page 6

1 006 clinical trials in Esslingen Am Neckar, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Esslingen Am Neckar at a glance
1 006
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 006 trials in Esslingen Am Neckar

Open in trial search

Study on Bortezomib and Drug Combination for Children with High-Risk Relapsed Acute Lymphoblastic Leukemia (ALL)

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Bortezomib
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Study on the Safety and Effectiveness of EIK1001 and Pembrolizumab for Patients with Advanced Melanoma

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Eikon Therapeutics Inc.

Study of Camizestrant for Patients with ER+/HER2- Early Breast Cancer After 2 Years of Standard Endocrine Therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:AstraZeneca AB

Breast cancer

Recruiting

Study of Tersolisib and a drug combination for adults with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Eli Lilly & Co.

First-line treatment of metastatic non‑small cell lung cancer with high PD‑L1 expression: ivonescimab versus pembrolizumab

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ivonescimab
  • Sponsor:Summit Therapeutics Inc.

Phase 2 Study of Oral VS-7375 in Adults with Advanced KRAS G12D‑Mutated Non‑Small Cell Lung Cancer Previously Treated

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:GFH375
  • Sponsor:Verastem Inc.

Study of BI 764532 with drug combination in patients with extensive‑stage small cell lung cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Boehringer Ingelheim Espana S.A.

Safety and Tolerability of ETHY-001 Compared with Saline 0.9% in Adults with Thyroid Eye Disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · Healthy volunteers
  • Sponsor:Ethyreal Bio Inc.

Efficacy and Safety of BI 1015550 in Adults with Fibrosing Interstitial Lung Disease at Risk of Disease Progression: A Randomized, Placebo‑Controlled Trial

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nerandomilast
  • Sponsor:Boehringer Ingelheim Espana S.A.

A Phase II Randomized, Double‑Blind Study of RO7568282 for Safety and Efficacy in Early‑Stage Parkinson’s Disease Patients

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Efficacy and Safety of Oral PIPE-791 in Adults with Idiopathic Pulmonary Fibrosis: A Phase 2 Randomized, Double‑Blind, Placebo‑Controlled Study

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:PIPE-791
  • Sponsor:Contineum Therapeutics Inc.

Phase 3 Study of GSK6042981 versus Imatinib in Adults with Previously Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors (GIST)

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib Mesilate
  • Sponsor:Glaxosmithkline Research & Development Limited

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Esslingen Am Neckar

What the registry says about research in the country

01 Lung Cancer Research

Extensive studies focusing on non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), evaluating novel treatment combinations and targeted therapies for various disease stages.

  • Advanced and metastatic disease management
  • Post-surgical treatment optimization
  • Combination therapy approaches

Multiple trials investigating immunotherapy combinations and targeted treatments for improved patient outcomes.

02 Breast Cancer Studies

Innovative research targeting hormone receptor-positive and triple-negative breast cancer, exploring new therapeutic strategies and treatment combinations.

  • Early-stage disease management
  • HER2-negative breast cancer
  • Perioperative treatment approaches

Focus on developing personalized treatment strategies and improving survival outcomes.

03 Hematologic Malignancies

Groundbreaking studies in chronic lymphocytic leukemia (CLL) and related blood cancers, evaluating novel drug combinations and treatment duration strategies.

  • Treatment optimization
  • Disease monitoring approaches
  • Targeted therapy combinations

Research aimed at improving treatment responses and patient quality of life.

04 Gastrointestinal Cancers

Research focusing on hepatocellular carcinoma and gastric cancer, investigating innovative combination therapies and surgical approaches.

  • Advanced disease treatment
  • Perioperative therapy
  • Immunotherapy applications

Studies evaluating novel treatment strategies for improved patient outcomes.

05 Gynecologic Oncology

Clinical trials in ovarian cancer and related conditions, studying maintenance therapies and combination treatments for advanced disease.

  • First-line treatment strategies
  • Maintenance therapy optimization
  • Targeted treatment approaches

Focus on improving survival rates and treatment effectiveness.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.